• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

MediPharm Labs Names Experienced Pharma and Med Tech Executive David Pidduck, as CEO


MediPharm Labs Corp., a pharmaceutical company specializing in precision-based cannabinoids, today announced that it has appointed experienced Pharma and Med Tech executive David Pidduck as Chief Executive Officer and Director of the Company. Mr. Pidduck replaces outgoing CEO and Director Bryan Howcroft, who is stepping down for personal reasons, effective today.

Mr. Pidduck brings more than 20 years of proven senior leadership experience to MediPharm, including serving as President and CEO of a Canadian pharmaceutical company, where he was also a member of the board of directors.

Chris Taves, Chairman of the Board commented, "We are very pleased to welcome David Pidduck to MediPharm. The Company continues to make progress building its sales pipeline both in Canada and internationally, driving toward consistent revenue growth and profitability."

David Pidduck, incoming CEO added, "I have watched the development of the medical cannabinoid industry over the past several years with great interest from my vantage point within the Pharma sector. Though the industry is still developing, cannabinoid research interest continues to grow, and I believe we may be approaching an inflection point where cannabinoids will become a larger focus for traditional Pharma. Medical cannabinoid companies are not created equal. In MediPharm, I see one of the very few organizations globally that has the required sophistication to both operate within a stringent Pharma environment, and scale rapidly to capitalize on this growth opportunity. I look forward to contributing my experience in business and corporate development to the team's current efforts, with a focus on orienting the Company toward both consistent organic growth and accretive M&A activities to drive revenue growth, profitability and value for all stakeholders."

Related Videos
Related Content